Off-Patent Industry Must Become ‘Focal Point’ For Health Systems Post-COVID
Medicines For Europe And IGBA Set Out Policy Priorities At Athens Conference
Off-patent medicines must become the “focal point” of pharmaceutical policies across the world as health systems recover from the COVID-19 pandemic, Medicines for Europe and the IGBA have urged as they held their joint annual conference in Athens, Greece.
